Maravai Lifesciences Holdings (MRVI) AI Stock Analysis

• Market Cap: $735.97M
• Dividend Yield: N/A
• Average Volume (3M): 1.84M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.62
• Revenue Growth: -11.76%
• EPS Growth: -15.82%
• Country: US
• Employees: 570
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 143,975,430
• 10 Day Avg. Volume: 2,137,655
• 30 Day Avg. Volume: 1,844,155
• PEG Ratio: -0.05
• Price to Book (P/B): 0.86
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.56
• Enterprise Value/Market Cap: 0.46
• Enterprise Value/Revenue: 0.31
• Enterprise Value/Gross Profit: 3.35
• Enterprise Value/Ebitda: 0.19
• 1Y Price Target: $4.17
• Price Target Upside: 44.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8

• Rating: 53 Neutral
• Price Target: $2.50 ▼(-13.49%Downside)

Maravai Lifesciences Holdings faces notable financial hurdles, with profitability and cash flow challenges being the most critical factors weighing on the stock score. Technical analysis shows some short-term positive momentum but is overshadowed by longer-term bearish trends. Recent earnings guidance was positive, but ongoing profitability issues and geopolitical risks complicate the outlook. Valuation remains a concern due to negative earnings and the absence of dividends.

Positive Factors

Leadership and Management

Raj Asarpota's extensive experience in leading global acquisitions and driving operational efficiencies is aligned with the company's focus on financial discipline.

Strategic Developments

The leadership transition is seen as a strategic alignment with the company's goals of enhancing value creation and operational efficiency.

Negative Factors

Financial Guidance

The company has not updated its full-year 2025 financial guidance, leaving investors uncertain about future financial performance.

Revenue Challenges

Maravai's non-COVID business has declined year-over-year for nine consecutive quarters, indicating persistent challenges in its key end-markets.

Maravai Lifesciences Holdings Business Overview & Revenue Model

Company Description

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.

How the Company Makes Money

Maravai Lifesciences Holdings makes money primarily through the sale of its life science products and services. The company generates revenue by providing high-quality reagents and services that are critical in the development and manufacturing processes of biopharmaceuticals and diagnostics. Key revenue streams include nucleic acid products, which are essential for mRNA-based therapies and vaccines, biologics safety testing for ensuring the safety and efficacy of drugs, and protein detection products used in research and development. Significant partnerships with biotech firms and research institutions also contribute to its earnings by expanding its market reach and customer base.

Maravai Lifesciences Holdings Financial Statement Overview

Summary

Maravai Lifesciences Holdings faces significant financial challenges as evidenced by declining revenues, profitability, and cash flows. Despite a strong cash position and reduced leverage, the company needs to address its revenue and profitability issues to improve its financial health. The biotechnology industry is competitive, and the company must navigate these challenges to stabilize and grow.

Income Statement

The income statement shows a concerning decline in revenue and profitability. Total revenue decreased from $883 million in 2022 to $259 million in 2024, indicating significant revenue contraction. Gross profit margin also declined, and the company reported negative EBIT and net income in 2024, reflecting operational and profitability challenges.

Balance Sheet

The balance sheet is moderately stable with some concerns. The debt-to-equity ratio improved from 1.42 in 2023 to 0.11 in 2024, indicating reduced leverage. However, ROE is negative due to net losses, and the equity ratio has decreased over the years. The company's cash position is strong, but the overall asset base is shrinking.

Cash Flow

Cash flow analysis reveals declining free cash flow, which dropped from $607 million in 2023 to a negative $22 million in 2024, signaling potential liquidity issues. The operating cash flow to net income ratio is low, suggesting inefficiency in converting net income to cash flow. However, operating cash flows remain positive, providing some cushion.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	259.19M	288.94M	883.00M	799.24M	284.10M
Gross Profit	108.31M	140.20M	714.04M	658.68M	204.45M
EBITDA	-156.92M	712.41M	609.99M	585.78M	138.27M
Net Income	-144.85M	-119.03M	490.66M	469.25M	76.89M
Balance Sheet
Total Assets	1.01B	1.49B	2.28B	1.92B	1.27B
Cash, Cash Equivalents and Short-Term Investments	322.40M	574.96M	632.14M	551.27M	236.18M
Total Debt	376.69M	610.97M	585.26M	534.31M	590.78M
Total Liabilities	431.04M	697.57M	1.38B	1.37B	1.12B
Stockholders Equity	325.29M	416.75M	545.22M	315.50M	88.51M
Cash Flow
Free Cash Flow	-22.19M	60.67M	518.89M	353.72M	126.78M
Operating Cash Flow	7.46M	126.22M	535.98M	368.57M	152.19M
Investing Cash Flow	-24.32M	-122.31M	-267.61M	105.66M	6.07M
Financing Cash Flow	-234.47M	-61.09M	-187.50M	-159.05M	53.21M

Maravai Lifesciences Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.89
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRVI, the sentiment is Positive. The current price of 2.89 is above the 20-day moving average (MA) of 2.39, above the 50-day MA of 2.25, and below the 200-day MA of 4.28, indicating a neutral trend. The MACD of 0.16 indicates Negative momentum. The RSI at 71.42 is Negative, neither overbought nor oversold. The STOCH value of 90.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MRVI.

Maravai Lifesciences Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAR	66 Neutral	$706.69M	―	-6.33%	―	23.92%	-27.69%
MRVI	53 Neutral	$735.97M	―	-45.75%	―	-11.76%	-15.82%
Sector *	52 Neutral	$7.59B	0.30	-61.86%	2.27%	16.72%	1.10%
BCAX	48 Neutral	$541.00M	―	34.94%	―	―	―
LENZ	46 Neutral	$964.29M	―	-24.47%	―	―	68.93%
IMNM	46 Neutral	$778.76M	―	-69.21%	―	-13.76%	57.73%
COGT	37 Underperform	$1.18B	―	-84.04%	―	―	-2.53%

Maravai Lifesciences Holdings Corporate Events

Maravai Lifesciences Appoints New CFO Rajesh Asarpota

On June 22, 2025, Maravai LifeSciences announced the appointment of Rajesh Asarpota as Chief Financial Officer, effective June 30, 2025, succeeding Kevin Herde. Mr. Asarpota, with extensive experience in finance and strategic growth in the life sciences and medical device sectors, will lead Maravai’s financial and strategic initiatives, supporting its focus on nucleic acid technologies and bioprocess impurity analytics. This transition aims to strengthen Maravai’s leadership team and drive long-term value creation for stakeholders.

The most recent analyst rating on (MRVI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Maravai Lifesciences Holdings stock, see the MRVI Stock Forecast page.

Maravai Lifesciences Appoints Bernd Brust as New CEO

On June 8, 2025, Maravai LifeSciences Holdings appointed Bernd Brust as the new CEO and member of the Board, succeeding William E. Martin, III. This leadership transition aims to enhance innovation and financial performance, with Brust bringing over 30 years of experience in the life sciences industry. The company is poised for long-term success with a strong financial foundation and a commitment to expanding its market leadership in mRNA and bioprocess impurity detection. Maravai plans to continue delivering innovative solutions to researchers and biotech innovators globally.

The most recent analyst rating on (MRVI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Maravai Lifesciences Holdings stock, see the MRVI Stock Forecast page.

Maravai Lifesciences Holds Annual Shareholders Meeting

On May 22, 2025, Maravai LifeSciences Holdings, Inc. conducted its Annual Meeting of Shareholders. During the meeting, shareholders elected directors for three-year terms, ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025, and approved the compensation of the company’s named executive officers on a non-binding advisory basis.

The most recent analyst rating on (MRVI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Maravai Lifesciences Holdings stock, see the MRVI Stock Forecast page.